The initial wave of Generative AI excitement in the life sciences is meeting a sobering reality: the “Implementation Gauntlet.” While the potential for AI to revolutionize the DMTA cycle is undisputed, many organizations remain trapped in “Pilot Purgatory,” unable to scale individual successes into enterprise-wide impact. Our latest whitepaper, “From Hype to Implementation,” deconstructs this […]
From Hype To Implementation Read More »
I recently found myself catching up on tweets, and I came across this repost by Michael Gilman, CEO of Arrakis Therapeutics, and I was reminded that over the past 20 years we’ve seen an explosive redefinition of the edges of druggable space. The nucleus of that explosion was the human genome project. In my own
Expanding Druggable Space Read More »
A Johns Hopkins article about creating an in-house coronavirus test reminded me of a project at the University of Houston, where we developed a pathogen-identifying technology. This technology, now feasible with modern computing, aimed to quickly identify pathogens without isolation, potentially saving lives.
Finding the Genomic Signatures of Pathogens Read More »
A few years ago, Luke Timmerman of Xconomy wrote about the 21 Red Flags in biotech investing and Sally Church of the Pharmastrategy Blog wrote a related post on Red Flags in clinical trials and cancer research. Here are a few additions of my own that I’d like to add to those lists. Context is
Red Flags in Drug Discovery Read More »
A recent discovery may hold the key to understanding cachexia, a common co-morbidity in cancer patients.
Putting the right information in front of the right people is an integral part of pharmaceutical project management. Learn how we make this easier in Pipeline.
Pipeline Stories: No More Gantt Charts Read More »
Learn how you can use podcasts to keep up to date in areas like genomics, bioinformatics, cancer research, drug discovery and drug development.
